Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
{{output}}
Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs abundantly express somatostatin receptors. Consequently, following administration... ...
